辉瑞宣布疫苗试验结果积极，股价大涨
许多制药公司因为与新冠疫情有关的好消息而股价大涨，跨国巨头辉瑞（Pfizer）也成为了其中之一。
辉瑞宣布一种新冠疫苗的早期试验取得积极的结果，消息传出后，周三下午，该公司股票大涨超过5%。
辉瑞与德国生物制药公司BioNTech合作进行了此次试验。BioNTech 的首席执行官乌古尔•萨欣表示，试验发现，进展最快的四种针对新型冠状病毒的候选疫苗“能够在人体中产生中和抗体反应”。
辉瑞的疫苗研发负责人凯瑟琳•詹森称，公司“对临床数据感到鼓舞”，并且计划“尽快在一本同行评审期刊上发布”这些数据。
辉瑞指出，虽然个别试验对象在接种疫苗后出现了“低烧”等副作用，但试验“没有导致严重的不良反应”。
辉瑞和BioNTech都表示，在这则好消息之后，两家公司将开展更大规模的疫苗试验，可能有3万人参与试验。该试验正在等待监管审批，可能在7月末之前开始。两家制药公司表示他们的最终计划是在“2020年年底之前生产1亿剂疫苗，在2021年年底之前生产超过12亿剂。”
除辉瑞和BioNTech，还有很多公司正在研发预防性新冠疫苗的制药公司。目前有十多种不同疫苗正在进行人体试验，或者预计将很快开始试验。
其中进展最快的疫苗来自Moderna Therapeutics公司。位于马萨诸塞州剑桥的Moderna在5月中旬公布了积极的早期试验结果。与辉瑞一样，消息传出后，该公司的股价同样大涨。（财富中文网）
译者：Biz
许多制药公司因为与新冠疫情有关的好消息而股价大涨，跨国巨头辉瑞（Pfizer）也成为了其中之一。
辉瑞宣布一种新冠疫苗的早期试验取得积极的结果，消息传出后，周三下午，该公司股票大涨超过5%。
辉瑞与德国生物制药公司BioNTech合作进行了此次试验。BioNTech 的首席执行官乌古尔•萨欣表示，试验发现，进展最快的四种针对新型冠状病毒的候选疫苗“能够在人体中产生中和抗体反应”。
辉瑞的疫苗研发负责人凯瑟琳•詹森称，公司“对临床数据感到鼓舞”，并且计划“尽快在一本同行评审期刊上发布”这些数据。
辉瑞指出，虽然个别试验对象在接种疫苗后出现了“低烧”等副作用，但试验“没有导致严重的不良反应”。
辉瑞和BioNTech都表示，在这则好消息之后，两家公司将开展更大规模的疫苗试验，可能有3万人参与试验。该试验正在等待监管审批，可能在7月末之前开始。两家制药公司表示他们的最终计划是在“2020年年底之前生产1亿剂疫苗，在2021年年底之前生产超过12亿剂。”
除辉瑞和BioNTech，还有很多公司正在研发预防性新冠疫苗的制药公司。目前有十多种不同疫苗正在进行人体试验，或者预计将很快开始试验。
其中进展最快的疫苗来自Moderna Therapeutics公司。位于马萨诸塞州剑桥的Moderna在5月中旬公布了积极的早期试验结果。与辉瑞一样，消息传出后，该公司的股价同样大涨。（财富中文网）
译者：Biz
Add multinational giant Pfizer to the list of pharmaceutical companies that have seen their shares jump on a dose of good, coronavirus-related news.
Pfizer’s stock was up more than 5% on Wednesday afternoon, after the company reported positive results in an early trial for a potential COVID-19 vaccine.
The trial, which Pfizer is conducting alongside German biopharma firm BioNTech, found that the most advanced of four vaccine candidates being vetted “is able to produce neutralizing antibody responses in humans” against the coronavirus, according to BioNTech CEO Ugur Sahin.
Kathrin Jansen, Pfizer’s head of vaccine research and development, said the company is “encouraged by the clinical data” and is planning to publish the clinical data “in a peer-reviewed journal as quickly as possible.”
While some of the trial subjects experienced side effects, including “low-grade fever,” after receiving doses of the vaccine, Pfizer said that “no serious adverse events were reported” as a result of the trial.
The positive news could lead to a larger trial for the vaccine potentially involving up to 30,000 subjects, Pfizer and BioNTech said. That trial could begin by late July, pending regulatory approval. Eventually, the pharmaceuticals would be prepared to manufacture “up to 100 million doses of the vaccine by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021,” they said.
Pfizer and BioNTech are far from the only pharma players currently working on a preventative vaccine for COVID-19. More than a dozen different potential vaccines are either currently in human trials or expected to begin them soon.
Among the most advanced is a vaccine being developed by Moderna Therapeutics. Like Pfizer, Cambridge, Mass.-based Moderna saw its stock soar after announcing positive early-stage trial results in mid-May.
